CS712688A2 - Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production - Google Patents

Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production

Info

Publication number
CS712688A2
CS712688A2 CS887126A CS712688A CS712688A2 CS 712688 A2 CS712688 A2 CS 712688A2 CS 887126 A CS887126 A CS 887126A CS 712688 A CS712688 A CS 712688A CS 712688 A2 CS712688 A2 CS 712688A2
Authority
CS
Czechoslovakia
Prior art keywords
thienol
tetrahydrofuro
new
pyridine production
pyridine
Prior art date
Application number
CS887126A
Other languages
Czech (cs)
Other versions
CS273193B2 (en
Inventor
Albrecht Dr Harreus
Karl-Heinz Dr Weber
Gerhard Dr Walter
Werner Dr Stransky
Franz J Dr Kuhn
Gunter Dr Schingnitz
Helmut Dr Ensinger
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of CS712688A2 publication Critical patent/CS712688A2/en
Publication of CS273193B2 publication Critical patent/CS273193B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CS712688A 1987-10-29 1988-10-27 Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production CS273193B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873736664 DE3736664A1 (en) 1987-10-29 1987-10-29 TETRAHYDRO-FURO- AND -THIENO (2,3-C) PYRIDINE, THEIR USE AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF

Publications (2)

Publication Number Publication Date
CS712688A2 true CS712688A2 (en) 1990-06-13
CS273193B2 CS273193B2 (en) 1991-03-12

Family

ID=6339349

Family Applications (1)

Application Number Title Priority Date Filing Date
CS712688A CS273193B2 (en) 1987-10-29 1988-10-27 Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production

Country Status (17)

Country Link
EP (1) EP0314154A3 (en)
JP (1) JPH01157983A (en)
KR (1) KR890006650A (en)
AU (1) AU2443588A (en)
CS (1) CS273193B2 (en)
DD (1) DD283395A5 (en)
DE (1) DE3736664A1 (en)
DK (1) DK603588A (en)
FI (1) FI884947A7 (en)
HU (1) HU201553B (en)
IL (1) IL88184A0 (en)
NO (1) NO884835L (en)
PL (1) PL275555A1 (en)
PT (1) PT88899B (en)
SU (1) SU1657064A3 (en)
YU (1) YU201288A (en)
ZA (1) ZA888089B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (en) * 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5272148A (en) * 1992-09-09 1993-12-21 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarenylpiperazines
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2703697C (en) * 2000-07-06 2012-09-04 Daiichi Sankyo Company, Limited Acid addition salts of hydropyridine derivatives
US20040048795A1 (en) * 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
CA2593079C (en) 2004-12-27 2014-08-19 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
TWI392681B (en) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd Prasugrel with high purity and a method for preparing its acid addition salt
WO2008108291A1 (en) * 2007-03-02 2008-09-12 Daiichi Sankyo Company, Limited Process for production of prasugrel hydrochloride having high purity
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (en) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 For the nerve cuff with bag portion without wire stimulator
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102821814B (en) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 Neurostimulation devices and systems for treating chronic inflammation
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (en) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 Control of vagus nerve stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4566539A1 (en) 2020-05-21 2025-06-11 The Feinstein Institutes for Medical Research Systems and methods for vagus nerve stimulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (en) * 1975-06-27 1977-01-21 Parcor NEW DERIVATIVES OF THIENO (2,3-C) PYRIDINE, THEIR PREPARATION AND THEIR APPLICATIONS
FR2317303A1 (en) * 1975-07-09 1977-02-04 Parcor PROCESS FOR PREPARING TETRAHYDROTHIENO (3,2-C) AND (2,3-C) PYRIDINE DERIVATIVES

Also Published As

Publication number Publication date
EP0314154A3 (en) 1990-12-05
JPH01157983A (en) 1989-06-21
FI884947A0 (en) 1988-10-27
DD283395A5 (en) 1990-10-10
NO884835D0 (en) 1988-10-28
AU2443588A (en) 1989-07-13
DE3736664A1 (en) 1989-05-11
NO884835L (en) 1989-05-02
FI884947L (en) 1989-04-30
YU201288A (en) 1990-08-31
DK603588D0 (en) 1988-10-28
HUT50824A (en) 1990-03-28
HU201553B (en) 1990-11-28
CS273193B2 (en) 1991-03-12
FI884947A7 (en) 1989-04-30
KR890006650A (en) 1989-06-15
ZA888089B (en) 1990-07-25
PT88899B (en) 1993-01-29
PL275555A1 (en) 1989-05-02
SU1657064A3 (en) 1991-06-15
DK603588A (en) 1989-04-30
IL88184A0 (en) 1989-06-30
EP0314154A2 (en) 1989-05-03

Similar Documents

Publication Publication Date Title
CS712688A2 (en) Method of new tetrahydrofuro- and -thienol (2,3-c) pyridine production
CS8701093A2 (en) Method of new cycloalkano/1,2-b/-indolesulphoamides production
LTIP830A (en) Pyridine derivatives,process for their production,herbicidal method and compositions
CS242188A2 (en) Method of 6-substituted 2,3-dideoxynucleosides production
PT79913A (en) Preparation process of new 6-substituted furo-(3,4-c)-pyridine derivatives
PT78361B (en) Preparation process of new furo-(3,4-c)-pyridine derivatives
PT79511B (en) Preparation process of new 6-vinyl-furo-(3,4-c)-pyridine derivatives
HUT37939A (en) Process for producing benzopyrano/ and - thiopyrano/ pyridines
CS567989A2 (en) Method of substituted 1,3,5-triazintriones production
PL279057A1 (en) Method for manufacturing new derivatives of 2-imine-1,3,4-dihydrothiadiazol
PT81365A (en) Preparation process of new 6-phenethylaminoalkyl-furo-(3,4-c)-pyridine derivatives
PT79369A (en) Preparation process of new 4-chloro-furo-(3,4-c)-pyridine derivatives
CS850787A2 (en) Method of substituted 1-phenoxy-3-amino-2-propanols production
CS415888A2 (en) Method of new acylderivatives production
CS40588A2 (en) Method of new isoxale derivatives production
HUT38345A (en) Process for producing 4,5,6,7-tetrahydrofuro- or -1h-pyrrolo/2,3-c/pyridine derivatives and pharmaceutical compositions containing them
PT81054A (en) New preparation process of 6-substituted-furo-(3,4-c)-pyridine derivatives
PT81087A (en) Preparation process of new 6-aminomethyl-furo-(3,4-c)-pyridine derivatives
CS1009187A2 (en) Method of new aminoalkanoyl-dibenzo (d,g) (1,3,6) dioxazocines production
CS281587A1 (en) Method of 1,1-dichloro-4-methyl-1,3-pentadiene production
CS357188A1 (en) Method of pentaerythril-tetrakis-/-3-/3,5-ditere-butyl-4-oxophenyl/propionate production
CS225489A2 (en) Method of new dihydropyridinamides production
CS457088A2 (en) Method of new n-organooxycarbamates production
CS61588A2 (en) Method of new n-organooxycarbamates production
CS399788A1 (en) Method of 9,10-antraquinone production